TRT Gel denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for trt gel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Step Therapy to Testosterone Gel

UnitedHealthcare's step-therapy (also called "fail-first") protocol for testosterone gel requires that patients try one or more lower-cost or preferred testosterone formulations before the plan will approve the requested gel product. Typically this means demonstrating a trial of a formulary-preferred injectable testosterone, a different gel brand, or another formulation before coverage of the requested product is authorized. A step-therapy denial does not mean the medication is inappropriate — it means the plan's administrative hurdle has not yet been cleared.

## Your Federal Appeal Rights

• Step-therapy exception / internal appeal (ERISA §503 / ACA §2719): File within 180 days of denial. UHC must respond within 30 days (72 hours expedited).
• Step-therapy override (many states): Numerous states have enacted step-therapy reform laws requiring plans to grant exceptions when a patient has already failed a required step, when the required step is contraindicated, or when the required step is expected to cause adverse effects for this patient. Check whether your state's law applies to your plan type.
• External review: After a final internal denial, escalate to an independent review organization within approximately four months. The IRO's decision is binding.

## Grounds for a Step-Therapy Exception

Federal and state standards generally require a plan to grant a step-therapy exception when any of the following applies:

1. Prior failure: The patient already tried the required step-therapy product(s) and experienced inadequate response or documented adverse effects. 2. Clinical contraindication: The required step product is clinically inappropriate for this patient for a reason documented in the medical record. 3. Clinical complexity: The patient's condition, comorbidities, or other clinical factors make the required step unreasonable, as documented by the prescriber.

## What to Gather

1. Prior-treatment records — pharmacy records and office notes for any previous testosterone formulation tried, with dates, duration, and documented outcome or adverse response. 2. Prescriber step-exception letter — explicitly addresses each required step product and explains why it was tried and failed, is contraindicated, or is otherwise clinically inappropriate for this patient. 3. Clinical documentation of need — current diagnosis confirmation, lab values, and symptom records demonstrating ongoing need for treatment. 4. State law reference (if applicable) — your prescriber's or attorney's reference to your state's step-therapy exception statute if your plan is subject to state insurance law. 5. FDA label for requested product — supporting the clinical rationale for the specific formulation requested.

## Criteria-Mapping Structure

Obtain UHC's current step-therapy protocol for testosterone products. Map each required step to the patient record:

| Required Step Product | Prior-Trial Evidence or Exception Ground | |---|---| | Step 1 product (identify from UHC policy) | [Date tried, outcome, or clinical contraindication] | | Step 2 product (if applicable) | [Date tried, outcome, or clinical rationale for skip] |

A peer-to-peer review between your prescriber and UHC's medical director is highly effective at the internal-appeal stage for step-therapy overrides — request one explicitly in your letter.